Immunomodulation by targeted anticancer agents.

Animals Antineoplastic Agents / immunology Disease Progression Humans Immunomodulation / immunology Neoplasms / immunology
BRAF CD8(+) cytotoxic T lymphocytes CDK4/CDK6 CGAS signaling DNA damage response EGFR KRAS T(REG) cells TGF-β immune checkpoint blockers immunogenic cell death

Journal

Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617

Informations de publication

Date de publication:
08 03 2021
Historique:
received: 30 09 2020
revised: 17 11 2020
accepted: 17 11 2020
pubmed: 19 12 2020
medline: 29 9 2021
entrez: 18 12 2020
Statut: ppublish

Résumé

At odds with conventional chemotherapeutics, targeted anticancer agents are designed to inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite such an elevated degree of molecular specificity, many clinically employed and experimental targeted anticancer agents also mediate immunostimulatory or immunosuppressive effects that (at least in some settings) influence therapeutic efficacy. Here, we discuss the main immunomodulatory effects of targeted anticancer agents and explore potential avenues to harness them in support of superior clinical efficacy.

Identifiants

DOI: 10.1016/j.ccell.2020.11.009 PMID: 33338426
pubmed: 33338426
pii: S1535-6108(20)30601-2
doi: 10.1016/j.ccell.2020.11.009
pii:
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

310-345

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests L.Z. reports research funding from Bristol Myers Squibb, Roche, Glaxo Smyth Kline, Lytix Pharma, Incyte, Merus, and Tusk and Pileje (completed); from Innovate Pharma, Kaleido, Transgene, Elior, Carrefour (ongoing); consulting/advisory honoraria from Transgene, EpiVax, and Lytix; and a co-founder role in everImmune. G.K. reports research funding from Bayer HealthCare, Genentech, Glaxo Smyth Kline, Institut Mérieux, Lytix, PharmaMar, and Sotio and Vasculox (completed); funding from Samsara; consulting/advisory honoraria from The Longevity Labs and Lytix; membership of the Executive Board of Bristol Myers Squibb Foundation France; and co-founder roles with everImmune, Samsara therapeutics, and Therafast Bio. L.G. reports research funding from Lytix and Phosplatin (completed), and consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, The Longevity Labs, Inzen, and the Luke Heller TECPR2 Foundation. All other authors have no conflicts of interest to declare.

Auteurs

Giulia Petroni (G)

Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.

Aitziber Buqué (A)

Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.

Laurence Zitvogel (L)

Gustave Roussy Cancer Center, Villejuif, France; INSERM U1015, Villejuif, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France; Faculty of Medicine, Paris-Saclay University, Le Kremlin-Bicêtre, France.

Guido Kroemer (G)

Equipe Labellisée Par La Ligue Contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France; Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China; Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden. Electronic address: kroemer@orange.fr.

Lorenzo Galluzzi (L)

Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; Sandra and Edward Meyer Cancer Center, New York, NY, USA; Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA; Department of Dermatology, Yale School of Medicine, New Haven, CT, USA; Université de Paris, Paris, France. Electronic address: deadoc80@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Immunomodulation by targeted anticancer agents.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Immunomodulation by targeted anticancer agents.
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Immunomodulation by targeted anticancer agents.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Immunomodulation by targeted anticancer agents.
questionsmedicales.fr › Phénomènes du système immunitaire › Immunomodulation › Immunomodulation by targeted anticancer agents.
questionsmedicales.fr › Tumeurs › Immunomodulation by targeted anticancer agents.